SATSUMA PHARMACEUTICALS INC's ticker is STSA and the CUSIP is 80405P107. A total of 46 filers reported holding SATSUMA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $642,981 | -22.4% | 920,517 | 0.0% | 0.00% | – |
| Q4 2022 | $828,465 | -84.8% | 920,517 | +1.2% | 0.00% | – |
| Q3 2022 | $5,457,000 | +105.8% | 909,390 | +42.0% | 0.00% | – |
| Q2 2022 | $2,651,000 | +7.6% | 640,364 | -1.2% | 0.00% | – |
| Q1 2022 | $2,463,000 | -16.4% | 648,332 | -1.0% | 0.00% | – |
| Q4 2021 | $2,946,000 | -2.2% | 654,846 | +1.3% | 0.00% | – |
| Q3 2021 | $3,013,000 | -33.7% | 646,513 | +0.3% | 0.00% | – |
| Q2 2021 | $4,542,000 | +263.4% | 644,301 | +204.5% | 0.00% | – |
| Q1 2021 | $1,250,000 | +43.7% | 211,560 | +12.1% | 0.00% | – |
| Q4 2020 | $870,000 | +5.6% | 188,808 | -10.8% | 0.00% | – |
| Q3 2020 | $824,000 | -92.6% | 211,735 | -45.5% | 0.00% | – |
| Q2 2020 | $11,179,000 | +93.7% | 388,700 | +45.0% | 0.00% | – |
| Q1 2020 | $5,771,000 | -3.2% | 268,153 | -11.4% | 0.00% | – |
| Q4 2019 | $5,959,000 | +1032.9% | 302,793 | +765.1% | 0.00% | – |
| Q3 2019 | $526,000 | – | 35,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 3,711,286 | $22,268,000 | 3.58% |
| NEA Management Company, LLC | 3,142,958 | $18,858,000 | 0.94% |
| Vivo Capital, LLC | 1,232,394 | $7,394,000 | 0.82% |
| RA Capital Management | 5,914,252 | $35,486,000 | 0.76% |
| Nan Fung Group Holdings Ltd | 177,900 | $1,067,000 | 0.68% |
| Ikarian Capital, LLC | 400,000 | $2,400,000 | 0.48% |
| SAMLYN CAPITAL, LLC | 2,929,195 | $17,575,000 | 0.33% |
| EAM Investors, LLC | 149,029 | $894,000 | 0.19% |
| TPG GP A, LLC | 1,885,939 | $11,316,000 | 0.18% |
| Ikarian Capital, LLC | 136,059 | $815,000 | 0.16% |